Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
First Dept. of Medicine, Athens University Medical School, Laikon Hospital, 11527 Athens, Greece. yrombos@otenet.gr. BACKGROUND AND OBJECTIVE: Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-o...
Gespeichert in:
| Veröffentlicht in: | Haematologica (Roma) 2000-02, Vol.85 (2), p.115-117 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 117 |
|---|---|
| container_issue | 2 |
| container_start_page | 115 |
| container_title | Haematologica (Roma) |
| container_volume | 85 |
| creator | Rombos, Y Tzanetea, R Konstantopoulos, K Simitzis, S Zervas, C Kyriaki, P Kavouklis, M Aessopos, A Sakellaropoulos, N Karagiorga, M Kalotychou, V Loukopoulos, D |
| description | First Dept. of Medicine, Athens University Medical School, Laikon Hospital, 11527 Athens, Greece. yrombos@otenet.gr.
BACKGROUND AND OBJECTIVE: Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS: A group of 11 thalassaemic patients entered the study; L1, the Cipla formulation for deferiprone, at a daily dose of 75-100 mg/kg bw t.i.d. was used. After giving informed consent all patients were subjected to clinical examination and biological tests. RESULTS: All patients tolerated the L1 well; there were no significant side effects (except for slight gastrointestinal disturbances for the first days). The net urinary iron excretion ranged from 6.96 to 26.1 mg/24h. Serum ferritin declined within 4-6 months in most of the patients. INTERPRETATION AND CONCLUSIONS: The results suggest that L1 is a rather safe drug which decreases iron overload without causing any considerable side-effects in Greek thalassemics. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_10681716</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10681716</sourcerecordid><originalsourceid>FETCH-LOGICAL-h266t-a1cc739e9fa2c5aeb3e9f5c14a486c883454ee870cebbc5385349ab20f34e9bf3</originalsourceid><addsrcrecordid>eNpFj11LwzAUhoMobk7_guRCQS8K-WjS5FKGXzDwRq_LaXa6RtquJJ1l_97oJl6dw_s-PPCekDlXVmSmEPyUzJm0LNOsMDNyEeMnY4JZW5yTGWfa8ILrOcFlgy2MftvTscEAw576ng4pwX6MdPJjkwpoIUbsPNBd9P3mB6XbAG27p-BG_4XUh2Rwv65toGusMfghZUjvVvz-kpzV0Ea8Ot4F-Xh6fF--ZKu359flwyprhNZjBty5Qlq0NQinACuZXuV4DrnRzhiZqxzRFMxhVTkljZK5hUqwWuZoq1ouyPXBO-yqDtflEHwHYV_-7U3AzRGA6KCtA_TOx39OGqt5nrDbA9b4TTP5gGXs0tpkFeU0TUaVouRcyW-uqm4N</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><creator>Rombos, Y ; Tzanetea, R ; Konstantopoulos, K ; Simitzis, S ; Zervas, C ; Kyriaki, P ; Kavouklis, M ; Aessopos, A ; Sakellaropoulos, N ; Karagiorga, M ; Kalotychou, V ; Loukopoulos, D</creator><creatorcontrib>Rombos, Y ; Tzanetea, R ; Konstantopoulos, K ; Simitzis, S ; Zervas, C ; Kyriaki, P ; Kavouklis, M ; Aessopos, A ; Sakellaropoulos, N ; Karagiorga, M ; Kalotychou, V ; Loukopoulos, D</creatorcontrib><description>First Dept. of Medicine, Athens University Medical School, Laikon Hospital, 11527 Athens, Greece. yrombos@otenet.gr.
BACKGROUND AND OBJECTIVE: Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS: A group of 11 thalassaemic patients entered the study; L1, the Cipla formulation for deferiprone, at a daily dose of 75-100 mg/kg bw t.i.d. was used. After giving informed consent all patients were subjected to clinical examination and biological tests. RESULTS: All patients tolerated the L1 well; there were no significant side effects (except for slight gastrointestinal disturbances for the first days). The net urinary iron excretion ranged from 6.96 to 26.1 mg/24h. Serum ferritin declined within 4-6 months in most of the patients. INTERPRETATION AND CONCLUSIONS: The results suggest that L1 is a rather safe drug which decreases iron overload without causing any considerable side-effects in Greek thalassemics.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>PMID: 10681716</identifier><language>eng</language><publisher>Pavia: Haematologica</publisher><subject>Administration, Oral ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Humans ; Iron Chelating Agents - administration & dosage ; Iron Chelating Agents - adverse effects ; Medical sciences ; Pharmacology. Drug treatments ; Pyridones - administration & dosage ; Pyridones - adverse effects ; Thalassemia - drug therapy ; Thalassemia - physiopathology ; Treatment Outcome</subject><ispartof>Haematologica (Roma), 2000-02, Vol.85 (2), p.115-117</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1389614$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10681716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rombos, Y</creatorcontrib><creatorcontrib>Tzanetea, R</creatorcontrib><creatorcontrib>Konstantopoulos, K</creatorcontrib><creatorcontrib>Simitzis, S</creatorcontrib><creatorcontrib>Zervas, C</creatorcontrib><creatorcontrib>Kyriaki, P</creatorcontrib><creatorcontrib>Kavouklis, M</creatorcontrib><creatorcontrib>Aessopos, A</creatorcontrib><creatorcontrib>Sakellaropoulos, N</creatorcontrib><creatorcontrib>Karagiorga, M</creatorcontrib><creatorcontrib>Kalotychou, V</creatorcontrib><creatorcontrib>Loukopoulos, D</creatorcontrib><title>Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>First Dept. of Medicine, Athens University Medical School, Laikon Hospital, 11527 Athens, Greece. yrombos@otenet.gr.
BACKGROUND AND OBJECTIVE: Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS: A group of 11 thalassaemic patients entered the study; L1, the Cipla formulation for deferiprone, at a daily dose of 75-100 mg/kg bw t.i.d. was used. After giving informed consent all patients were subjected to clinical examination and biological tests. RESULTS: All patients tolerated the L1 well; there were no significant side effects (except for slight gastrointestinal disturbances for the first days). The net urinary iron excretion ranged from 6.96 to 26.1 mg/24h. Serum ferritin declined within 4-6 months in most of the patients. INTERPRETATION AND CONCLUSIONS: The results suggest that L1 is a rather safe drug which decreases iron overload without causing any considerable side-effects in Greek thalassemics.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Humans</subject><subject>Iron Chelating Agents - administration & dosage</subject><subject>Iron Chelating Agents - adverse effects</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridones - administration & dosage</subject><subject>Pyridones - adverse effects</subject><subject>Thalassemia - drug therapy</subject><subject>Thalassemia - physiopathology</subject><subject>Treatment Outcome</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFj11LwzAUhoMobk7_guRCQS8K-WjS5FKGXzDwRq_LaXa6RtquJJ1l_97oJl6dw_s-PPCekDlXVmSmEPyUzJm0LNOsMDNyEeMnY4JZW5yTGWfa8ILrOcFlgy2MftvTscEAw576ng4pwX6MdPJjkwpoIUbsPNBd9P3mB6XbAG27p-BG_4XUh2Rwv65toGusMfghZUjvVvz-kpzV0Ea8Ot4F-Xh6fF--ZKu359flwyprhNZjBty5Qlq0NQinACuZXuV4DrnRzhiZqxzRFMxhVTkljZK5hUqwWuZoq1ouyPXBO-yqDtflEHwHYV_-7U3AzRGA6KCtA_TOx39OGqt5nrDbA9b4TTP5gGXs0tpkFeU0TUaVouRcyW-uqm4N</recordid><startdate>20000201</startdate><enddate>20000201</enddate><creator>Rombos, Y</creator><creator>Tzanetea, R</creator><creator>Konstantopoulos, K</creator><creator>Simitzis, S</creator><creator>Zervas, C</creator><creator>Kyriaki, P</creator><creator>Kavouklis, M</creator><creator>Aessopos, A</creator><creator>Sakellaropoulos, N</creator><creator>Karagiorga, M</creator><creator>Kalotychou, V</creator><creator>Loukopoulos, D</creator><general>Haematologica</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20000201</creationdate><title>Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)</title><author>Rombos, Y ; Tzanetea, R ; Konstantopoulos, K ; Simitzis, S ; Zervas, C ; Kyriaki, P ; Kavouklis, M ; Aessopos, A ; Sakellaropoulos, N ; Karagiorga, M ; Kalotychou, V ; Loukopoulos, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h266t-a1cc739e9fa2c5aeb3e9f5c14a486c883454ee870cebbc5385349ab20f34e9bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Humans</topic><topic>Iron Chelating Agents - administration & dosage</topic><topic>Iron Chelating Agents - adverse effects</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridones - administration & dosage</topic><topic>Pyridones - adverse effects</topic><topic>Thalassemia - drug therapy</topic><topic>Thalassemia - physiopathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rombos, Y</creatorcontrib><creatorcontrib>Tzanetea, R</creatorcontrib><creatorcontrib>Konstantopoulos, K</creatorcontrib><creatorcontrib>Simitzis, S</creatorcontrib><creatorcontrib>Zervas, C</creatorcontrib><creatorcontrib>Kyriaki, P</creatorcontrib><creatorcontrib>Kavouklis, M</creatorcontrib><creatorcontrib>Aessopos, A</creatorcontrib><creatorcontrib>Sakellaropoulos, N</creatorcontrib><creatorcontrib>Karagiorga, M</creatorcontrib><creatorcontrib>Kalotychou, V</creatorcontrib><creatorcontrib>Loukopoulos, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rombos, Y</au><au>Tzanetea, R</au><au>Konstantopoulos, K</au><au>Simitzis, S</au><au>Zervas, C</au><au>Kyriaki, P</au><au>Kavouklis, M</au><au>Aessopos, A</au><au>Sakellaropoulos, N</au><au>Karagiorga, M</au><au>Kalotychou, V</au><au>Loukopoulos, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2000-02-01</date><risdate>2000</risdate><volume>85</volume><issue>2</issue><spage>115</spage><epage>117</epage><pages>115-117</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>First Dept. of Medicine, Athens University Medical School, Laikon Hospital, 11527 Athens, Greece. yrombos@otenet.gr.
BACKGROUND AND OBJECTIVE: Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS: A group of 11 thalassaemic patients entered the study; L1, the Cipla formulation for deferiprone, at a daily dose of 75-100 mg/kg bw t.i.d. was used. After giving informed consent all patients were subjected to clinical examination and biological tests. RESULTS: All patients tolerated the L1 well; there were no significant side effects (except for slight gastrointestinal disturbances for the first days). The net urinary iron excretion ranged from 6.96 to 26.1 mg/24h. Serum ferritin declined within 4-6 months in most of the patients. INTERPRETATION AND CONCLUSIONS: The results suggest that L1 is a rather safe drug which decreases iron overload without causing any considerable side-effects in Greek thalassemics.</abstract><cop>Pavia</cop><pub>Haematologica</pub><pmid>10681716</pmid><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0390-6078 |
| ispartof | Haematologica (Roma), 2000-02, Vol.85 (2), p.115-117 |
| issn | 0390-6078 1592-8721 |
| language | eng |
| recordid | cdi_pubmed_primary_10681716 |
| source | MEDLINE; DOAJ Directory of Open Access Journals |
| subjects | Administration, Oral Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Humans Iron Chelating Agents - administration & dosage Iron Chelating Agents - adverse effects Medical sciences Pharmacology. Drug treatments Pyridones - administration & dosage Pyridones - adverse effects Thalassemia - drug therapy Thalassemia - physiopathology Treatment Outcome |
| title | Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T11%3A49%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chelation%20therapy%20in%20patients%20with%20thalassemia%20using%20the%20orally%20active%20iron%20chelator%20deferiprone%20(L1)&rft.jtitle=Haematologica%20(Roma)&rft.au=Rombos,%20Y&rft.date=2000-02-01&rft.volume=85&rft.issue=2&rft.spage=115&rft.epage=117&rft.pages=115-117&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E10681716%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10681716&rfr_iscdi=true |